FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy
FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy
复制标题
FADS1 调节接受奥氮平单药治疗的精神分裂症患者的代谢综合征
DOI：
10.1016/j.ajp.2020.102352
复制
发表时间：
2020-12-01
影响因子：
9.5
通讯作者：
Zhang, Chen
中科院分区：
文献类型：
--
作者：
Chen, Jianmin;Lu, Weihong;Zhang, Chen
在这项研究中，我们假设脂肪酸去饱和酶-1(FADS1)和脂肪酸去饱和酶-2(FADS2)可能在接受奥氮平单一治疗的患者中介导代谢综合征(METS)。共纳入216例精神分裂症患者。两组间FADS1mRNA表达差异有统计学意义(F=4.58，P=0.03)，而FADS2mRNA表达差异无统计学意义(F=1.29，P=0.26)。FADS1mRNA与高密度脂蛋白胆固醇呈正相关(P=0.04)，与收缩压呈负相关(P=0.04)。我们的发现提示FADS1可能是一个重要的遗传修饰物，可以调节奥氮平相关的代谢紊乱。
In this study, we hypothesized that fatty acid desaturase-1 (FADS1) and fatty acid desaturase-2 (FADS2) may mediate metabolic syndrome (MetS) in patients receiving olanzapine monotherapy. 216 schizophrenia patients were recruited. There is a significant difference between the patients with or without MetS in term of the expression of FADS1 mRNA (F = 4.58, P = 0.03), but not FADS2 mRNA (F = 1.29, P = 0.26). We observed a positive association between FADS1 mRNA and high-density lipoprotein cholesterol (P = 0.04), and a negative association between FADS1 mRNA and systolic blood pressure (P = 0.04). Our findings implied that FADS1 may be an important genetic modifier that can regulate olanzapine-associated metabolic disturbance.